RxDoctor Payments Data

Christopher Connolley, MD

Gastroenterology · Winston Salem, NCNPI 1396702767

Payments from drug & device makers

$78,046in general payments, 2019–2025

Across 99 payments — averaging $788.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$33K
  • Janssen Research & Development, LLC$25K
  • Bausch Health US, LLC$15K
  • AbbVie$4K
  • Fujifilm Healthcare Americas Corporation$241
  • Pfizer$218
  • plus $638 from 16 others
$2,113in research payments, 2019–2025

Across 2 payments — averaging $1056.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Speaking & faculty fees$3,20066%
  • Food & beverage$1,38729%
  • Gifts$1503%
  • Other$912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,046 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$322,982
Medicare patients
350
Services billed
11,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab41$1,105,264
LinzessLinaclotide110$69,026
CreonLipase/Protease/Amylase14$35,030
DexilantDexlansoprazole12$9,773
Dexlansoprazole DrDexlansoprazole16$7,080
TrulancePlecanatide15$6,608
Ursodiol40$5,341
MotegrityPrucalopride Succinate11$5,318
Omeprazole264$4,880
Dicyclomine Hcl120$3,174
Pantoprazole Sodium227$2,718
Lansoprazole26$2,665
Lubiprostone18$2,548
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,503
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$2,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$47$1,105,26441 claims
AbbVieLinzess, Creon$3,732$104,056124 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant, Motegrity$84$15,09123 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$56$6,60815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →